Lisette van der Molen

Lisette van der Molen

Auto-generated profile, based on publicly available information

Lisette van der Molen

Department of Head and Neck Oncology and Surgery, The Netherlands Cancer Institute, Amsterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications


1 March 2013 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
LMLisette van der Molen
Lisette van der Molen
WHWilma D. Heemsbergen
Wilma D. Heemsbergen
RJRianne de Jong
Rianne de Jong
MRMaya A. van Rossum
Maya A. van Rossum
LSLudi E. Smeele
Ludi E. Smeele
FHFrans J.M. Hilgers
Frans J.M. Hilgers

15 November 2009 in BMC Ear, Nose and Throat Disorders
Verified
Journal Article
Open access
PDF file
LMLisette van der Molen
Lisette van der Molen
MRMaya A van Rossum
Maya A van Rossum
AAAnnemieke H Ackerstaff
Annemieke H Ackerstaff
LSLudi E Smeele
Ludi E Smeele
CRCoen Rn Rasch
Coen Rn Rasch
FHFrans Jm Hilgers
Frans Jm Hilgers
Background: Aim of this study is to thoroughly assess pretreatment organ function in advanced head and neck cancer through various clinical outcome measures and patients' views. Methods: A comprehensive, multidimensional assessment was used, that included quality of life, swallowing, mouth opening, and weight changes. Fifty-five patients with stage III-IV disease were entered in this study prior to organ preserving (chemoradiation) treatment. Results: All patients showed pretreatment abnormalities or problems, identified by one or more of the outcome measures. Most frequent problems concerned swallowing, pain, and weight loss. Interestingly, clinical outcome measures and patients' perception did no always concur. E.g. videofluoroscopy identified aspiration and laryngeal penetration in 18% of the patients, whereas only 7 patients (13%) perceived this as problematic; only 2 out of 7 patients with objective trismus actually perceived trismus. Conclusion: The assessment identified several problems already pre-treatment, in this patient population. A thorough assessment of both clinical measures and patients' views appears to be necessary to gain insight in all (perceived) pre-existing functional and quality of life problems.

28 July 2013 in European Archives of Oto-Rhino-Laryngology
Verified
Journal Article
Closed access
PDF file
LMLisette van der Molen
Lisette van der Molen
MRMaya A. van Rossum
Maya A. van Rossum
CRCoen R. N. Rasch
Coen R. N. Rasch
LSLudi E. Smeele
Ludi E. Smeele
FHFrans J. M. Hilgers
Frans J. M. Hilgers

3 November 2011 in BMC Cancer
Verified
Journal Article
Open access
PDF file
VRValesca P. Retel
Valesca P. Retel
LMLisette van der Molen
Lisette van der Molen
FHFrans Jm Hilgers
Frans Jm Hilgers
CRCoen Rn Rasch
Coen Rn Rasch
ALAnnemiek Aamhj L'ORtye
Annemiek Aamhj L'ORtye
WHWim van Harten
Wim van Harten
Background: Concomitant chemo-radiotherapy (CCRT) has become an indispensable organ, but not always function preserving treatment modality for advanced head and neck cancer. To prevent/limit the functional side effects of CCRT, special exercise programs are increasingly explored. This study presents cost-effectiveness analyses of a preventive (swallowing) exercise program (PREP) compared to usual care (UC) from a health care perspective.Methods: A Markov decision model of PREP versus UC was developed for CCRT in advanced head and neck cancer. Main outcome variables were tube dependency at one-year and number of post-CCRT hospital admission days. Primary outcome was costs per quality adjusted life years (cost/QALY), with an incremental cost-effectiveness ratio (ICER) as outcome parameter. The Expected Value of Perfect Information (EVPI) was calculated to obtain the value of further research.Results: PREP resulted in less tube dependency (3% and 25%, respectively), and in fewer hospital admission days than UC (3.2 and 4.5 days respectively). Total costs for UC amounted to €41,986 and for PREP to €42,271. Quality adjusted life years for UC amounted to 0.68 and for PREP to 0.77. Based on costs per QALY, PREP has a higher probability of being cost-effective as long as the willingness to pay threshold for 1 additional QALY is at least €3,200/QALY. At the prevailing threshold of €20,000/QALY the probability for PREP being cost-effective compared to UC was 83%. The EVPI demonstrated potential value in undertaking additional research to reduce the existing decision uncertainty.Conclusions: Based on current evidence, PREP for CCRT in advanced head and neck cancer has the higher probability of being cost-effective when compared to UC. Moreover, the majority of sensitivity analyses produced ICERs that are well below the prevailing willingness to pay threshold for an additional QALY (range from dominance till €45,906/QALY).